Skip to main content

Psychotic Disorders

0
Pipeline Programs
12
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Integrated Biosciences
Integrated BiosciencesCA - San Carlos
2 programs
PASIM programN/A1 trial
Peer-facilitated, Recovery-based Self-illness-management programmeN/A1 trial
Active Trials
NCT07129369Not Yet Recruiting186Est. Oct 2028
NCT06487195Active Not Recruiting198Est. Aug 2027
Bristol Myers Squibb
1 program
AripiprazoleN/ASmall Molecule1 trial
Active Trials
NCT01739127Completed83Est. Feb 2016
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Family Focused Therapy for Clinical High Risk YouthN/A1 trial
Active Trials
NCT04338152Active Not Recruiting220Est. Dec 2026
Verona Pharma
Verona PharmaUK - London
1 program
Health Promotion InterventionN/A1 trial
Active Trials
NCT02807688Completed325Est. Mar 2014
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
Inpatient Care in a Closed Unit Incorporating Soteria ElementsN/A1 trial
Active Trials
NCT07836348Recruiting200Est. Jun 2029
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
Peer-Delivered Decision Support InterventionN/A1 trial
Active Trials
NCT04532034Completed12Est. Mar 2023
Alliance Pharmaceuticals
1 program
Risperdal Long Acting Injectable Antipsychotic MedicationN/A1 trial
Active Trials
NCT00287027Terminated60Est. Dec 2006
Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
SleepioN/A1 trial
Active Trials
NCT04180709Completed45Est. Jul 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
BI 409306PHASE_21 trial
Active Trials
NCT03230097Terminated50Est. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Boehringer IngelheimBI 409306
Integrated BiosciencesPASIM program
Jerusalem PharmaceuticalsInpatient Care in a Closed Unit Incorporating Soteria Elements
Integrated BiosciencesPeer-facilitated, Recovery-based Self-illness-management programme
Angeles TherapeuticsFamily Focused Therapy for Clinical High Risk Youth
Cognition TherapeuticsSleepio
Temple TherapeuticsPeer-Delivered Decision Support Intervention
Bristol Myers SquibbAripiprazole
Verona PharmaHealth Promotion Intervention
Alliance PharmaceuticalsRisperdal Long Acting Injectable Antipsychotic Medication

Clinical Trials (10)

Total enrollment: 1,379 patients across 10 trials

NCT03230097Boehringer IngelheimBI 409306

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Start: Sep 2017Est. completion: Apr 202150 patients
Phase 2Terminated
NCT07129369Integrated BiosciencesPASIM program

Effects of a Peer-facilitated, Acceptance-based Self-learning for Illness Management (PASIM) Program

Start: Jan 2026Est. completion: Oct 2028186 patients
N/ANot Yet Recruiting
NCT07836348Jerusalem PharmaceuticalsInpatient Care in a Closed Unit Incorporating Soteria Elements

A Closed Unit Incorporating Soteria Elements Versus a Conventional Closed Psychiatric Ward

Start: Sep 2025Est. completion: Jun 2029200 patients
N/ARecruiting
NCT06487195Integrated BiosciencesPeer-facilitated, Recovery-based Self-illness-management programme

Effects of a Peer-facilitated, Recovery-focused Self-illness Management Program for First-episode Psychosis

Start: Feb 2023Est. completion: Aug 2027198 patients
N/AActive Not Recruiting
NCT04338152Angeles TherapeuticsFamily Focused Therapy for Clinical High Risk Youth

Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial

Start: Jan 2021Est. completion: Dec 2026220 patients
N/AActive Not Recruiting
NCT04180709Cognition TherapeuticsSleepio

CBT to Reduce Insomnia and Improve Social Recovery in Early Psychosis

Start: Oct 2020Est. completion: Jul 202345 patients
N/ACompleted
NCT04532034Temple TherapeuticsPeer-Delivered Decision Support Intervention

Facilitating Engagement in Evidence-Based Treatment for Early Psychosis

Start: Sep 2020Est. completion: Mar 202312 patients
N/ACompleted
NCT01739127Bristol Myers SquibbAripiprazole

Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

Start: Nov 2012Est. completion: Feb 201683 patients
N/ACompleted
NCT02807688Verona PharmaHealth Promotion Intervention

Physical Co-morbidity, Poor Health Behaviour and Health Promotion in Verona Patients With Functional Psychoses

Start: Mar 2012Est. completion: Mar 2014325 patients
N/ACompleted
NCT00287027Alliance PharmaceuticalsRisperdal Long Acting Injectable Antipsychotic Medication

Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication

Start: Feb 2006Est. completion: Dec 200660 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,379 patients
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.